Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib, Tacrolimus, and Sirolimus for aGVHD Prophylaxis in Myelofibrosis
NCT02528877Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Nov 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by City of Hope. Planned start Nov 2015; status: withdrawn.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02528877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528877.